Quality Lapses Across States: Rajasthan Joins West Bengal In Flagging Defective CE-Marked Medical Devices

A quiet recall order issued in Rajasthan earlier this month has once again brought the spotlight back on the safety of medical devices used in government hospitals.

Coming soon after a major catheter supply scandal in West Bengal, the latest development suggests that concerns around quality and oversight may not be limited to a single state, but point to a deeper, nationwide regulatory challenge.

For patients admitted to public hospitals, trust rests not only on doctors but also on the medical devices used during treatment. Over the past year, however, official records from different states have shown that problems in critical care devices are sometimes detected only after they have already entered hospital wards.

Rajasthan Orders Recall of Neonatal Catheters

On January 5, 2026, the Rajasthan Medical Services Corporation (RMSC) issued a formal order directing the recall and replacement of multiple batches of Neonatal PICC catheters supplied to government hospitals. The devices were manufactured by Vygon India Pvt Ltd, the Indian subsidiary of a France-based multinational.

The recall followed a technical evaluation carried out by subject experts, who found that the catheters did not meet the flow-rate specifications mentioned in state tenders. The order, signed by the Executive Director (Quality Control) and approved by the Managing Director of RMSC, declared the affected batches unfit for use or distribution.

RMSC also instructed that the entire stock of the identified batches be withdrawn immediately from warehouses and replaced with compliant material.

Why Flow-Rate Deviations Matter?

According to official documents, the flow rates of the PUR-XRO PICC catheters supplied in Rajasthan deviated from the specifications laid down in procurement contracts. Neonatal PICC lines are commonly used in intensive care units, where newborns require highly controlled and precise drug delivery.

In neonatal care, even small deviations in flow rate can have serious or life-threatening consequences. Experts note that newborns survive on extremely fine physiological margins, making device accuracy critical.

While the Rajasthan order was framed as a procedural corrective step, it has raised wider concerns about how such deviations went unnoticed until after supply and distribution.

Echoes of the West Bengal Catheter Scam

The Rajasthan action comes close on the heels of a much more serious episode reported earlier in West Bengal. In that case, the state government confirmed that substandard oximetry CVC catheters had been supplied to major government hospitals, including Calcutta Medical College.

Official orders issued by health authorities documented unauthorised substitution of manufacturers and serious quality assurance lapses.

The multinational supplier involved was subsequently blacklisted from state tenders for two years after it emerged that low-quality, locally sourced catheters were allegedly packed in branded boxes and passed off as premium antibacterial products.

Despite the gravity of the West Bengal findings, there was no public advisory or directive calling for a nationwide review of similar devices supplied elsewhere.

CE-Marked Devices, Yet Quality Failures

A troubling aspect common to both cases is that the devices involved carried international certifications, including CE marking. These were not unapproved or unregistered products, but devices cleared under existing national and international regulatory frameworks.

When quality failures surface in CE-marked devices across multiple states within a short time, it raises questions that go beyond individual procurement lapses. Healthcare observers argue that certification alone cannot replace active monitoring once products enter hospital supply chains.

Gaps in Post-Marketing Surveillance

The emerging pattern highlights possible weaknesses in post-marketing surveillance of medical devices. While approvals and standards are defined at the national level, oversight appears to weaken once devices are procured and deployed.

In both Rajasthan and West Bengal, state authorities acted only after problems were detected locally. There is still no indication of a coordinated national review or shared alert mechanism to assess whether similar devices are being used elsewhere under identical conditions.

Private Healthcare Remains a Blind Spot

Another concern is the limited reach of state procurement agencies. Their authority typically ends with government hospitals within their own states. Yet, nearly 75 percent of patients in India receive treatment in private healthcare facilities.

In the absence of a clear and enforceable system to transmit alerts beyond state procurement networks, it remains unclear how risks identified in public hospitals are communicated to private providers using similar devices.

With multiple states flagging quality lapses in critical care medical devices, the issue has moved beyond isolated incidents. It now raises broader questions about national oversight, accountability, and coordination.

So far, there has been no comprehensive response from the Central Drugs Standard Control Organization (CDSCO), the central authority responsible for regulating medical devices in India.

For patients, these regulatory gaps remain invisible until something goes wrong. As states continue to act independently, healthcare experts say the need of the hour is a transparent, nationwide system that detects, shares, and responds to such risks before they reach hospital beds.